Fig. 6

PTPRH enhanced glycolysis in vivo and in vitro. A Xenograft tumor sizes in the sh-PTPRH and sh-negative control (sh-NC) groups. B, C The volume and weight of tumors in the sh-PTPRH group were significantly decreased compared to those in the sh-NC group. D Representative hematoxylin–eosin (H&E) images of Ki67 and PTPRH staining in A549 xenografts. E, F Representative micro-PET images of mice in the sh-PTPRH and sh-NC groups. The closer the color of the tumor within the circle of mice is to red means the higher accumulation of ¹⁸F-FDG. The accumulation of ¹⁸F-FDG in the tumors of sh-NC-treated mice was significantly greater than that in the tumors of sh-PTPRH-treated mice. G Representative immunostained images of PTPRH, GLUT1, HK2, PKM2, and LDHA staining in A549 xenografts. H Cellular ¹⁸F‐FDG uptake was significantly decreased in the sh-PTPRH group and increased in the PTPRH-overexpressing (OE-PTPRH) group. I Lactate levels in the culture medium of the sh-PTPRH-treated group were significantly decreased, whereas they were increased in the OE-PTPRH-treated group. J Relative expression levels of glycolysis-related proteins in the sh-PTPRH and sh-NC groups by western blotting